Use of an Imaging Device after Nonablative Radiofrequency (Pellevé) Treatment For Periorbital Rhytids

Reynaldo M. Javate, MD
Raul T. Cruz Jr., M.D.
Use of an Imaging Device after Nonablative Radiofrequency (Pellevé) Treatment For Periorbital Rhytids

Reynaldo M. Javate, MD
Raul T. Cruz Jr., M.D.

Lacrimal, Orbital and Oculofacial Plastic Surgery
Department of Ophthalmology
University of Santo Tomas Hospital
University of Santo Tomas, Manila, Philippines
Pellevé™ today...

Safe and effective
- Minimal downtime
- Noninvasive
- Minimal discomfort
- Minimal side effects
- No anesthetic required

...out on the town tonight
Purpose of the Study

• To use an imaging device in objective photo-documentation of the effect of nonablative radiofrequency (Pellevé) treatment on periorbital rhytids.
Materials and Methods

• 12 Patients age 30-60 y/o underwent 1-2 sessions of Nonablative Radiofrequency Treatment to the periorbital region
• Energy output setting of 15 to 40.
• Fluke thermometer set at 40 to 42 degrees centigrade

Method: Patient Selection

- Lower tissue mobility
- Lower photoaging values
- Shallower wrinkle or fold depth

Position the client and press 'take picture' to capture the picture.
Capture will take several seconds and there will be 2 flashes.

Correct positioning for front view
Instruct client to close eyes.
Before RF (Pellevé)

After RF (Pellevé)
Results and Discussion

Before RF (Pellevé)  After RF (Pellevé)
MEAN EYEBROW LIFT BEFORE AND AFTER THE TREATMENT

<table>
<thead>
<tr>
<th>Eyebrow Elevations</th>
<th>Mean ± SEM</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>15.07 ± 1.20</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Immediately After</td>
<td>17.12 ± 1.15</td>
<td></td>
</tr>
<tr>
<td>Immediately After</td>
<td>17.12 ± 1.15</td>
<td></td>
</tr>
<tr>
<td>After 2 weeks</td>
<td>17.36 ± 1.15</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>After 4 weeks</td>
<td>17.48 ± 1.14</td>
<td></td>
</tr>
<tr>
<td>After 6 weeks</td>
<td>18.00 ± 1.13</td>
<td></td>
</tr>
<tr>
<td>After 8 weeks</td>
<td>18.59 ± 1.21</td>
<td></td>
</tr>
</tbody>
</table>

* p-value displayed is based from test statistic $F(d_1 = 1, d_2 = 13) = 253.95, p<0.001$
† p-value displayed is based from test statistic $F(d_1 = 4, d_2 = 52) = 67.00, p<0.001$

AVERAGE EYEBROW LIFT

Relative to the baseline, patients exhibited an average increase of 2.05 mm of eyebrow lift immediately after treatment and 3.52 mm after 8 weeks.
MEAN EYELID CREASE BEFORE AND AFTER THE TREATMENT

**Eyelid Crease**

<table>
<thead>
<tr>
<th></th>
<th>Mean ± SEM</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>3.23 ± 0.25</td>
<td></td>
</tr>
<tr>
<td>Immediately After</td>
<td>4.21 ± 0.27</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>After 2 weeks</td>
<td>4.30 ± 0.28</td>
<td></td>
</tr>
<tr>
<td>After 4 weeks</td>
<td>4.34 ± 0.28</td>
<td>&lt;0.001‡</td>
</tr>
<tr>
<td>After 6 weeks</td>
<td>4.61 ± 0.29</td>
<td></td>
</tr>
<tr>
<td>After 8 weeks</td>
<td>5.07 ± 0.26</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- **p-value displayed is based from test statistic F (df, = 1, df, = 13) = 85.30, p<0.001**
- **p-value displayed is based from test statistic F (df, = 4, df, = 52) = 60.65, p<0.001**

AVERAGE EYELID CREASE

Patients also exhibited eyelid crease increase of 0.98 mm immediately after treatment and 1.84 mm after 8 weeks. All the increase from the baseline, both of the eyebrow lift and eyelid crease, are statistically significant.
Conclusion

RF (Pellevé) application produces quantifiable changes such as brow elevation, elevation of the superior palpebral crease and improvements in periorbital rhytids and wrinkles shown and documented by using the Imaging Device.
Conclusion

Canfield Reveal Imager can be used in the objective photo-documentation of subtle and modest, but significant effects of RF (Pellevé) treatment to the periorbital region.
This material is intended to provide general information, including opinions and recommendations, contained herein for educational purposes only. Such information is not intended to be a substitute for professional medical advice, diagnosis or treatment. The material is not intended to direct clinical care in any specific circumstance. The judgment regarding a particular clinical procedure or treatment plan must be made by a qualified physician in light of the clinical data presented by the patient and the treatment options available.

This material may contain uses of Ellman devices for skin tightening in areas other than the face which are investigational and have not been approved by the U.S. Food and Drug Administration. Please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events prior to using these devices. Federal Law (USA) restricts these devices to sale, distribution, or use by or on the order of a physician.

As a manufacturer of wrinkle treatment systems, Ellman International, Inc. has an interest, commitment and responsibility to stay current with the latest advancements and achievements in this area.